MGB Biopharma and Almac’s Sciences Business Unit have entered into a collaboration where Almac will manufacture the production of their lead gram positive antibacterial compound MGB-BP3.
The compound is a DNA minor groove binder and is currently in pre-clinical development with IND filing targeted for Q3 2012. CEO Dr Miroslav Ravic said “We were very quickly impressed with the approach taken by Almac and they have already shown an intuitive understanding of what it takes to support a small company like ours. We look forward to a continued successful relationship.”
Following on from their expertise in early phase and steady growth in late phase clinical development, Almac recently announced a capacity expansion within its API facility, further leveraging its API and Drug Product integrated offering.
Date: January 17, 2012